SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug DevelopmentNovember 19, 2025 4:30 PM EST | Source: SureNano Science Ltd.Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with GlucaPharm Inc. ("GlucaPharm"), to conduct legal, technical and financia ...

Core Viewpoint - SureNano Science Ltd. is planning a private placement to raise up to $1,250,000 through the sale of units, which will include common shares and purchase warrants [1][2]. Group 1: Private Placement Details - The private placement will consist of up to 10,000,000 units priced at $0.125 each, with each unit comprising one common share and one warrant [2]. - Each warrant allows the holder to purchase one common share at $0.35 for 24 months, with an acceleration provision if the share price exceeds $0.50 for ten consecutive trading days [2]. - Finders introducing subscribers may receive a 6% cash commission and 6% in common share purchase warrants, also exercisable at $0.35 for 24 months [3]. Group 2: Use of Proceeds - Proceeds from the private placement will be allocated for operating expenses, including legal and audit fees, and general working capital [3]. - The company aims to explore new markets for its SureNano™ surfactant and investigate complementary industries [3]. Group 3: Company Overview - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, a food-grade compound for high-performance nanoemulsions [5]. - The company holds an exclusive license to distribute the SureNano™ surfactant in Canada, Oklahoma, and Colorado [5].

Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has closed a private placement financing of 2,450,000 common shares at a price of $0.10 per share. Total proceeds of $245,000 were received by the Company, including $85,000 in debt conversion. The Company intends to use the cash proceeds for operating expenses, including legal and audit fees and general working capital. No part of the proceed ...